Genome deal seeks to accelerate pore sequencing

January 2009
Nature;1/15/2009, Vol. 457 Issue 7227, p248
Academic Journal
The article reports that the San Diego, California based biotechnology company Illumina purchased all rights to market, sell and distribute products based on the DNA sequencing technology belonging to Oxford Nanopore Technologies of Great Britain. This technique identifies sequences by passing DNA through pores made from proteins.


Related Articles

  • GENE MACHINE. Herper, Matthew // Forbes Asia;Jan2011, Vol. 7 Issue 1, p34 

    The article focuses on the gene decoder, Personal Genome Machine (PGM) invented by engineer and entrepreneur Jonathan Rothberg. It discusses different aspects of the machine which is a desktop decoder and is expected to initiate revolution in medicine, food, energy, even consumer products. The...

  • Oxford Nanopore, Illunima Seek Affordable Sequencing. Moran, Nuala // BioWorld International;1/14/2009, Vol. 14 Issue 2, p5 

    The article reports on the agreement signed by Oxford Nanopore Technologies Ltd. to commercialize its low-cost DNA sequencing technology with Illumina Inc., under which Illumina will exclusively market, sell, distribute, and service sequencers based on Oxford Nanopore's technology. Illumina also...

  • Nanopore DNA sequencing inches closer to commercial debut. Matthews, Jermey N. A. // Physics Today;Nov2012, Vol. 65 Issue 11, p29 

    The article reports on the possibility that a nanopore-sensing technique for deoxyribonucleic acid (DNA) sequencing will be commercially available. British-based biotechnology company Oxford Nanopore Technologies (ONT) declared that it was close to manufacturing a commercial nanopore sensor. A...

  • Illumina takes a $18M stake in UK firm Oxford Nanopore.  // Medical Device Daily;1/13/2009, Vol. 13 Issue 7, p3 

    The article reports that Illumina in San Diego, California, and Oxford Nanopore Technologies in Oxford, England, has entered a strategic alliance. It states that the alliance includes a commercialization agreement and equity investment. It talks about the terms of the commercialization agreement...

  • Material witness: Improving pore performance. Ball, Philip // Nature Materials;Nov2013, Vol. 12 Issue 11, p950 

    The author reflects on different efforts to develop nanopore technology for commercial molecular-sensing devices including gene sequencing. The author mention about a Great Britain-based company Oxford Nanopore Technologies Ltd. and the European project called nanoDNAsequencing. The author also...

  • Oxford's Opening Statement.  // Bio-IT World;Mar2009, Vol. 8 Issue 2, p10 

    The article reports that Oxford Nanopore Technologies has published its first proof of principle of its label-free next-generation sequencing technology in "Nature Nanotechnology." The paper by James Clarke and colleagues shows that an engineered nanopore can discriminate between the four bases...

  • Accelrys and Oxford Nanopore Enter Software Partnership for DNA Sequencing Data Analysis.  // Biomedical Market Newsletter;4/14/2011, p102 

    The article reports on the announcement by scientific enterprise research and development (R&D) software and services provider Accelrys Inc. regarding the partnership agreement it signed with Oxford Nanopore Technologies Ltd. It states that they will develop analyzing software for data produced...

  • How Many Planning to Join SHOP to Shop for Co. Health Plans? Keshavan, Meghana // San Diego Business Journal;11/25/2013, Vol. 34 Issue 47, p10 

    The article offers information on topics related to health care insurance industry in San Diego, California as of November 25, 2013. It discusses the Covered California's Small Business Health Options Program (SHOP) that is scheduled to go online on November 25. It mentions that the shares of...

  • Roche Abandons Hostile Takeover Bid for Illumina.  // MondayMorning;4/23/2012, Vol. 20 Issue 17, p1 

    The article discusses the rejection of F. Hoffmann-La Roche Ltd. of Switzerland for buyout of Illumina Inc. of California. It mentions that the investors of the company are concerned about the company's gene-mapping technology. It adds that Oxford Nanopore Technologies Ltd. in Great Britain and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics